Skip to main content
NCBI home page
British Heart Journal logoLink to British Heart Journal
editorial
. 1995 Oct;74(4):337–340. doi: 10.1136/hrt.74.4.337

New directions in anticoagulant and antiplatelet treatment.

M L Simoons, J W Deckers
PMCID: PMC484033  PMID: 7488441

Full text

PDF
337

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albelda S. M., Buck C. A. Integrins and other cell adhesion molecules. FASEB J. 1990 Aug;4(11):2868–2880. [PubMed] [Google Scholar]
  2. Antman E. M. Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. Circulation. 1994 Oct;90(4):1624–1630. doi: 10.1161/01.cir.90.4.1624. [DOI] [PubMed] [Google Scholar]
  3. Cannon C. P., Maraganore J. M., Loscalzo J., McAllister A., Eddings K., George D., Selwyn A. P., Adelman B., Fox I., Braunwald E. Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease. Am J Cardiol. 1993 Apr 1;71(10):778–782. doi: 10.1016/0002-9149(93)90823-u. [DOI] [PubMed] [Google Scholar]
  4. Cannon C. P., McCabe C. H., Henry T. D., Schweiger M. J., Gibson R. S., Mueller H. S., Becker R. C., Kleiman N. S., Haugland J. M., Anderson J. L. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. J Am Coll Cardiol. 1994 Apr;23(5):993–1003. doi: 10.1016/0735-1097(94)90581-9. [DOI] [PubMed] [Google Scholar]
  5. Chesebro J. H., Fuster V. Dynamic thrombosis and thrombolysis. Role of antithrombins. Circulation. 1991 May;83(5):1815–1817. doi: 10.1161/01.cir.83.5.1815. [DOI] [PubMed] [Google Scholar]
  6. Coller B. S., Folts J. D., Smith S. R., Scudder L. E., Jordan R. Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/IIIa receptor. Correlation with bleeding time, platelet aggregation, and blockade of GPIIb/IIIa receptors. Circulation. 1989 Dec;80(6):1766–1774. doi: 10.1161/01.cir.80.6.1766. [DOI] [PubMed] [Google Scholar]
  7. Coller B. S. Platelets and thrombolytic therapy. N Engl J Med. 1990 Jan 4;322(1):33–42. doi: 10.1056/NEJM199001043220107. [DOI] [PubMed] [Google Scholar]
  8. Deutsch E., Rao A. K., Colman R. W. Selective thrombin inhibitors: the next generation of anticoagulants. J Am Coll Cardiol. 1993 Oct;22(4):1089–1092. doi: 10.1016/0735-1097(93)90420-6. [DOI] [PubMed] [Google Scholar]
  9. Gold H. K., Coller B. S., Yasuda T., Saito T., Fallon J. T., Guerrero J. L., Leinbach R. C., Ziskind A. A., Collen D. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation. Circulation. 1988 Mar;77(3):670–677. doi: 10.1161/01.cir.77.3.670. [DOI] [PubMed] [Google Scholar]
  10. Hirsh J. Heparin. N Engl J Med. 1991 May 30;324(22):1565–1574. doi: 10.1056/NEJM199105303242206. [DOI] [PubMed] [Google Scholar]
  11. Krupinski K., Breddin H. K., Markwardt F., Haarmann W. Antithrombotic effects of three thrombin inhibitors in a rat model of laser-induced thrombosis. Haemostasis. 1989;19(2):74–82. doi: 10.1159/000215893. [DOI] [PubMed] [Google Scholar]
  12. Lenfant C. NHLBI funding policies. Enhancing stability, predictability, and cost control. Circulation. 1994 Jul;90(1):1–1. doi: 10.1161/01.cir.90.1.1. [DOI] [PubMed] [Google Scholar]
  13. Lidón R. M., Théroux P., Juneau M., Adelman B., Maraganore J. Initial experience with a direct antithrombin, Hirulog, in unstable angina. Anticoagulant, antithrombotic, and clinical effects. Circulation. 1993 Oct;88(4 Pt 1):1495–1501. doi: 10.1161/01.cir.88.4.1495. [DOI] [PubMed] [Google Scholar]
  14. Neuhaus K. L., von Essen R., Tebbe U., Jessel A., Heinrichs H., Mäurer W., Döring W., Harmjanz D., Kötter V., Kalhammer E. Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK) Circulation. 1994 Oct;90(4):1638–1642. doi: 10.1161/01.cir.90.4.1638. [DOI] [PubMed] [Google Scholar]
  16. Simoons M. L., de Boer M. J., van den Brand M. J., van Miltenburg A. J., Hoorntje J. C., Heyndrickx G. R., van der Wieken L. R., de Bono D., Rutsch W., Schaible T. F. Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. European Cooperative Study Group. Circulation. 1994 Feb;89(2):596–603. doi: 10.1161/01.cir.89.2.596. [DOI] [PubMed] [Google Scholar]
  17. Topol E. J., Califf R. M., Weisman H. F., Ellis S. G., Tcheng J. E., Worley S., Ivanhoe R., George B. S., Fintel D., Weston M. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. Lancet. 1994 Apr 9;343(8902):881–886. doi: 10.1016/s0140-6736(94)90007-8. [DOI] [PubMed] [Google Scholar]
  18. Verstraete M., Nurmohamed M., Kienast J., Siebeck M., Silling-Engelhardt G., Büller H., Hoet B., Bichler J., Close P. Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. European Hirudin in Thrombosis Group. J Am Coll Cardiol. 1993 Oct;22(4):1080–1088. doi: 10.1016/0735-1097(93)90419-2. [DOI] [PubMed] [Google Scholar]
  19. Yasuda T., Gold H. K., Yaoita H., Leinbach R. C., Guerrero J. L., Jang I. K., Holt R., Fallon J. T., Collen D. Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation. J Am Coll Cardiol. 1990 Sep;16(3):714–722. doi: 10.1016/0735-1097(90)90364-u. [DOI] [PubMed] [Google Scholar]
  20. Zoldhelyi P., Webster M. W., Fuster V., Grill D. E., Gaspar D., Edwards S. J., Cabot C. F., Chesebro J. H. Recombinant hirudin in patients with chronic, stable coronary artery disease. Safety, half-life, and effect on coagulation parameters. Circulation. 1993 Nov;88(5 Pt 1):2015–2022. doi: 10.1161/01.cir.88.5.2015. [DOI] [PubMed] [Google Scholar]
  21. van den Bos A. A., Deckers J. W., Heyndrickx G. R., Laarman G. J., Suryapranata H., Zijlstra F., Close P., Rijnierse J. J., Buller H. R., Serruys P. W. Safety and efficacy of recombinant hirudin (CGP 39 393) versus heparin in patients with stable angina undergoing coronary angioplasty. Circulation. 1993 Nov;88(5 Pt 1):2058–2066. doi: 10.1161/01.cir.88.5.2058. [DOI] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES